Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
23.73
+0.33 (1.41%)
At close: Apr 20, 2026, 4:00 PM EDT
24.20
+0.47 (1.98%)
After-hours: Apr 20, 2026, 4:36 PM EDT
Pulse Biosciences Employees
Pulse Biosciences had 116 employees as of December 31, 2025. The number of employees increased by 41 or 54.67% compared to the previous year.
Employees
116
Change (1Y)
41
Growth (1Y)
54.67%
Revenue / Employee
$3,017
Profits / Employee
-$627,422
Market Cap
1.61B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 116 | 41 | 54.67% |
| Dec 31, 2024 | 75 | 19 | 33.93% |
| Dec 31, 2023 | 56 | -5 | -8.20% |
| Dec 31, 2022 | 61 | -81 | -57.04% |
| Dec 31, 2021 | 142 | 47 | 49.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| DENTSPLY SIRONA | 14,000 |
| ICU Medical | 13,000 |
| Warby Parker | 4,036 |
| Azenta | 3,000 |
| AtriCure | 1,350 |
| STAAR Surgical Company | 921 |
| LeMaitre Vascular | 655 |
| Kestra Medical Technologies | 330 |
PLSE News
- 11 hours ago - Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Business Wire
- 3 days ago - Pulse Biosciences to Host Analyst Event on April 25, 2026 - Business Wire
- 11 days ago - Pulse Biosciences Strengthens Executive Leadership Team - Business Wire
- 13 days ago - Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation - Business Wire
- 18 days ago - Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference - Business Wire
- 4 weeks ago - Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data - Business Wire
- 5 weeks ago - Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology - Business Wire
- 6 weeks ago - Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Business Wire